What does Zevra Therapeutics do?
Zevra Therapeutics, Inc. is a commercial-stage rare-disease company listed on the Nasdaq Global Select Market under ZVRA. Its current model is unusually concentrated: it acquires or licenses medicines that already have meaningful clinical evidence, then applies regulatory, market-access, and patient-support capabilities to move them through approval and commercialization. The company describes this evolution in its official corporate history, while its 2025 Form 10-K provides the operating and financial foundation.
Which medicines define the portfolio?
| Asset | Disease / status | Role in the model | Key economic feature |
|---|---|---|---|
| MIPLYFFA (arimoclomol) | Niemann-Pick disease type C; FDA approved in September 2024 | Primary commercial growth engine and strategic focus | U.S. product sales, global early-access revenue, and potential European expansion |
| OLPRUVA | Certain urea-cycle disorders; FDA approved in December 2022 | Commercial product retained while alternatives are evaluated | Small U.S. sales base with a 10% royalty obligation on eligible net sales |
| Celiprolol | Vascular Ehlers-Danlos syndrome; Phase 3 DiSCOVER trial | Potential next proprietary growth platform | No approved U.S. therapy for VEDS, but approval remains clinically and regulatorily uncertain |
Zevra is more than a pre-revenue biotechnology company, yet less diversified than mature specialty pharma. MIPLYFFA determines most commercial outcomes, celiprolol supplies much of the pipeline option value, and OLPRUVA illustrates launch risk in a small market. Concentration is the central analytical lens.
How does Zevra Therapeutics make money?
Zevra earns revenue through four mechanisms: U.S. product sales, global early-access program reimbursements, royalties from partnered products, and occasional asset monetizations. Its official product portfolio shows why the revenue base is narrow, while the latest filings show that MIPLYFFA has rapidly displaced legacy royalty economics as the dominant recurring source.
Which revenue stream mattered most in Q1 2026?
What is the commercialization mechanism?
| Revenue route | Customer / payer mechanics | Margin or cash-flow implication |
|---|---|---|
| MIPLYFFA U.S. sales | A single specialty pharmacy distributes to patients; insurers and government programs influence realized price through coverage, rebates, and discounts. | High-value rare-disease revenue, but gross-to-net reserves and patient onboarding determine cash conversion. |
| Global early access | Selected-country distributors support patients before formal local approval or reimbursement. | Meaningful near-term revenue, but it may change when commercial authorization and national reimbursement replace early access. |
| Partner royalties | Third parties commercialize licensed products and remit contractual royalties. | Historically asset-light, but the AZSTARYS arrangement ended following the March 2026 settlement. |
| Asset monetization | Zevra sells rights or regulatory assets, as with the 2025 priority review voucher and 2026 SDX portfolio transaction. | Can transform liquidity, but gains are nonrecurring and should not be capitalized as normal operating earnings. |
For valuation, the cleanest recurring base is MIPLYFFA product demand plus sustainable early-access or future ex-U.S. commercial revenue. Royalties and one-time asset sales matter to cash, but they obscure the underlying operating margin if treated as ordinary sales.
What does Zevra Therapeutics’ latest quarter show?
The latest official reporting period is the quarter ended March 31, 2026. Zevra’s Q1 2026 earnings release and Form 10-Q show rapid commercial growth, a debt-free balance sheet, and reported profit dominated by a transaction gain.
How much of the profit was recurring?
| Q1 metric | 2026 | 2025 | Interpretation |
|---|---|---|---|
| Net revenue | $36.2M | $20.4M | Growth came mainly from MIPLYFFA and the global early-access program. |
| R&D expense | $4.4M | $3.1M | Clinical investment rose as celiprolol and post-approval work progressed. |
| SG&A expense | $20.8M | $17.5M | Commercial infrastructure remains large relative to revenue. |
| Gain on asset sale | $43.3M | $0 | The Commave transaction drove most reported operating income. |
| Operating cash flow | $6.1M | $(8.6)M | A positive quarter is encouraging, but working capital and one-time items can make quarterly cash flow volatile. |
Management estimated adjusted net income of $11.5M, or $0.18 per diluted share, after excluding the asset-sale gain and other specified items. That measure is more informative than GAAP net income for the quarter, but sustainable profitability still depends on MIPLYFFA growth outpacing commercial and clinical spending.
Which turning points reshaped Zevra Therapeutics?
Zevra’s history is a sequence of strategic pivots. It began as KemPharm, built around prodrug discovery, and became a rare-disease commercialization platform. These events explain today’s revenue mix, balance sheet, and pipeline.
-
2006
KemPharm was incorporated, establishing the medicinal-chemistry and licensing foundation that later produced partnered assets.
-
2022
Management pivoted toward rare diseases and acquired selected Orphazyme assets, including arimoclomol and the commercial infrastructure that became central to MIPLYFFA.
-
2023
The company adopted the Zevra name and acquired Acer Therapeutics, adding OLPRUVA and celiprolol while increasing integration and execution demands.
-
2024
FDA approval of MIPLYFFA created the first approved U.S. treatment for NPC and converted Zevra into a product-revenue company.
-
2025
Zevra sold a priority review voucher for $150.0M gross proceeds and submitted MIPLYFFA’s European marketing application, pairing balance-sheet strength with geographic expansion.
-
2026
The company monetized its SDX-related portfolio, terminated the AZSTARYS license, and repaid its term loan, simplifying the story around rare disease and removing financial leverage.
What did the pivot change economically?
The pivot traded a capital-light royalty model for direct commercial economics. That increases revenue potential and strategic control, but it also creates payer, distribution, inventory, pharmacovigilance, and selling-cost exposure. It further makes acquisitions a core competence: value depends on selecting assets whose clinical evidence can be converted into approvals and durable patient access without overpaying or overbuilding infrastructure.
Why is MIPLYFFA the strategic center of Zevra?
MIPLYFFA is the first FDA-approved NPC treatment and is used with miglustat in patients aged two years and older. Because NPC is ultra-rare, progressive, and difficult to diagnose, success depends on finding patients, supporting specialty centers, securing coverage, and reducing treatment friction.
How strong is access and exclusivity?
MIPLYFFA has U.S. orphan-drug exclusivity through 2031, while patent protection and pending next-generation applications may extend aspects of the franchise. The company’s June 2026 announcement of a U.S. patent listing and its positive infant substudy publication add evidence and intellectual-property support, but neither removes reimbursement, competitive, or lifecycle risk.
Can celiprolol become Zevra’s next growth engine?
Celiprolol is being studied for vascular Ehlers-Danlos syndrome, a genetic disorder associated with arterial and organ rupture. Zevra estimates roughly 7,500 U.S. patients and no specifically approved U.S. therapy. Despite Breakthrough Therapy and Orphan Drug designations, timing depends on Phase 3 enrollment, clinical events, FDA alignment, and data quality.
What must happen before commercialization?
Where is research spending concentrated?
The official pipeline page makes clear that celiprolol is the principal late-stage asset. Its upside is strategically important because it could reduce dependence on NPC; its downside is equally important because a failed or delayed trial would leave Zevra reliant on MIPLYFFA and acquisitions for diversification.
Who are Zevra’s competitors, and what is its advantage?
Competition differs by franchise. MIPLYFFA faces IntraBio’s AQNEURSA and investigational NPC approaches. OLPRUVA faces established branded therapies and authorized generics. For celiprolol, the main present competitor is execution uncertainty: diagnosing VEDS, recruiting a rare population, and proving a regulatory-grade outcome.
| Arena | Competitive pressure | Zevra’s position | What could erode it |
|---|---|---|---|
| NPC treatment | Alternative approved and investigational therapies | First FDA-approved NPC therapy, established launch infrastructure, clinical evidence, and orphan exclusivity | Superior competitor data, easier administration, payer preference, or slower patient finding |
| Urea-cycle disorders | Entrenched branded products and lower-priced generics | Approved product and rare-disease commercial capabilities | Limited differentiation, pricing pressure, and low prescriber switching |
| Rare-disease asset acquisition | Specialty-pharma and biotech buyers seeking de-risked programs | Demonstrated ability to acquire, finance, and launch overlooked assets | Overpayment, integration failures, or competition for attractive programs |
What is the moat in practical terms?
The defensible resource is organizational: regulatory execution, rare-disease market access, patient services, and disciplined business development. Those capabilities can meet the resource-based tests of value and scarcity, but durability depends on repeated execution. A one-product franchise is not automatically a wide moat, even when the product has exclusivity.
How financially strong is Zevra Therapeutics?
Zevra’s balance sheet is stronger than its income statement suggests. The 2025 priority review voucher sale and 2026 SDX transaction supplied non-dilutive cash, while term-loan repayment removed leverage. At March 31, 2026, $236.8M of cash and investments equaled about five times current liabilities; the current ratio was approximately 4.9 times.
| Financial signal | FY2025 / Dec. 31, 2025 | Q1 2026 / Mar. 31, 2026 | Research interpretation |
|---|---|---|---|
| Revenue | $106.5M | $36.2M for the quarter | Commercial scale is rising, led by MIPLYFFA. |
| Operating result | $(62.9)M loss | $52.1M income | Both periods contain large noncash or nonrecurring items; normalized operating economics require adjustment. |
| Operating cash flow | $(1.6)M | $6.1M | Cash burn improved sharply, but one positive quarter does not establish a durable conversion rate. |
| Cash and investments | $238.9M | $236.8M | Liquidity remained broadly stable despite repaying debt. |
| Long-term debt | $61.9M | $0 | Debt removal lowers interest expense and financial risk. |
What should analysts normalize?
FY2025 net income of $83.2M was driven by the priority review voucher gain, while Q1 2026 GAAP income was driven by the SDX sale. Conversely, FY2025 included a $58.7M impairment charge and $11.7M of inventory obsolescence. A sensible normalized model begins with recurring product revenue, recurring cost of product revenue, SG&A, R&D, royalties, and working capital—then treats asset sales, impairments, and financing remeasurement separately.
Who owns Zevra stock, and how is it governed?
Zevra has one class of common stock with one vote per share, so economic ownership and voting power generally align. The 2026 proxy statement shows a dispersed governance structure rather than founder control.
| Holder / group | Shares | Ownership | Why it matters |
|---|---|---|---|
| BlackRock, Inc. | 4,080,420 | 6.9% | Large passive institutional ownership increases the importance of governance, liquidity, and disclosure quality. |
| Woodline Partners LP | 3,476,143 | 5.9% | A concentrated healthcare-oriented investor can have meaningful economic influence without control. |
| Neil McFarlane, CEO | 743,475 | 1.3% | Management has economic exposure, but no dominant voting block. |
| Directors and executive officers as a group | 2,202,989 | 3.7% | Strategy is accountable to a broadly held shareholder base. |
What governance signals matter?
Board chair Tamara Favorito is separate from CEO Neil McFarlane, reducing role concentration. 2025 performance stock units were tied to revenue goals, aligning incentives with commercialization. Researchers should distinguish 59.1M common shares outstanding at March 31, 2026 from the approximately 68.9M fully diluted Q1 count, which included awards and warrants and therefore matters for per-share valuation.
What opportunities and risks could change Zevra’s outlook?
The opportunity set is concentrated: deeper U.S. MIPLYFFA penetration, better NPC diagnosis, European authorization, celiprolol progress, and selective acquisitions. The mirror risks are single-product dependence, reimbursement friction, clinical uncertainty, supplier concentration, and capital deployed into unsuccessful deals.
How do the risks connect to financial statements?
| Risk or opportunity | Operational signal | Financial line affected | Valuation consequence |
|---|---|---|---|
| MIPLYFFA penetration | Diagnosis, enrollments, coverage, persistence | Product revenue, receivables, rebate liabilities | Changes near-term growth and terminal franchise value. |
| European expansion | Regulatory decision and national reimbursement | Early-access versus commercial revenue, launch expense | Adds geographic runway but may introduce price and timing variability. |
| Celiprolol trial | Enrollment, events, endpoint outcome | R&D expense and potential future product revenue | Produces a probability-weighted pipeline asset rather than current cash flow. |
| Supply and distributor concentration | Service continuity, inventory, collections | Revenue timing, cost of product revenue, working capital | Raises execution risk and may justify a higher discount rate. |
| Patent and exclusivity duration | Orange Book listings, challenges, lifecycle evidence | Long-run price and volume | Directly shapes terminal growth and the length of forecast cash flows. |
The most material strategic tension is clear: Zevra has enough liquidity to invest without immediate capital-market dependence, but its recurring economics remain concentrated in one young franchise. Capital allocation must balance MIPLYFFA launch execution, celiprolol development, and acquisitions without rebuilding the leverage or dilution risk that the 2025–2026 asset monetizations helped reduce.
Why does Zevra Therapeutics matter for valuation?
A conventional headline earnings multiple is a poor fit because GAAP results contain large asset-sale gains, impairments, and acquisition-related charges. A more decision-useful approach separates three value blocks: the commercial MIPLYFFA franchise, probability-adjusted pipeline value for celiprolol, and net cash, then subtracts corporate operating costs, contractual royalties, milestones, and dilution.
Which DCF assumptions carry the most weight?
The terminal-value assumption deserves restraint because product concentration and finite exclusivity make perpetual growth especially sensitive. Analysts can reduce that risk by forecasting explicit patient cohorts, geographic launches, royalty burdens, and post-exclusivity erosion rather than applying a generic pharmaceutical growth rate. Comparables are useful only when adjusted for commercial-stage status, product concentration, net cash, and pipeline maturity.
What is the key takeaway from Zevra Therapeutics analysis?
Zevra has completed a consequential transformation: it moved from a licensing-oriented development company to a rare-disease commercial operator with an approved flagship product, a late-stage pipeline asset, and a debt-free balance sheet. MIPLYFFA’s rapid revenue ramp and expanding evidence base support the strategy; the cash position gives management time to execute; and the company’s acquisition history shows an ability to extract value from assets that larger organizations may overlook.
The same facts create the principal weakness. MIPLYFFA supplies most recurring revenue, OLPRUVA has contributed little, and celiprolol remains unapproved. Reported profitability has also been shaped by exceptional transactions rather than a fully mature operating margin. The research task is therefore to monitor patient-level commercial quality, European progress, recurring cash conversion, DiSCOVER milestones, and disciplined use of the balance sheet.
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.